
International Application PCT/EP00/00135
Attorney Docket No.: BM45348



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ruelle et al. Serial No.: Unknown

Filed: Herewith

For: Novel Compounds

Crossp Art Unit No.: Unknown

Examiner: Unknown

PRELIMINARY AMENDMENT

Sir:

Applicant respectfully requests that this Preliminary Amendment be entered in this case before the calculation of fees and before examination of the subject application.

In the Claims:

Please delete the claims of the application as filed in the PCT and substitute therefor:

- 25. An isolated polypeptide comprising a member selected from the group consisting of
 - (a) an amino acid sequence matching one of SEQ ID NOs:2 (BASB051), 4 (BASB057), 6 (BASB060), 8 (BASB061), 10 (BASB063), 12 (BASB065), 14 (BASB066), or 16 (BASB071);
 - (b) an immunogenic polypeptide comprising a fragment sequence of at least 15 amino acids that matches an aligned contiguous segment of one of SEQ ID NOs: 4, 6, 8, 10, 12, 14, or 16;

wherein the isolated polypeptide, when administered to a subject in a suitable composition which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an antibody or T-cell immune response to a polypeptide having the sequence of one of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, or 16.

- 26. An isolated polynucleotide encoding a polypeptide of Claim 25 or the full complement to the isolated polynucleotide.
- 27. The isolated polypeptide of claim 25, wherein the polypeptide is according to (a).
- 28. An isolated polynucleotide encoding a polypeptide of Claim 27 or the full complement to the isolated polynucleotide.

